Success Metrics

Completion Rate

0%(0/1)

Active Trials

2(50%)

Terminated

1(25%)

Phase Distribution

Ph phase_2

25%

Ph not_applicable

25%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(1)

Other(1)

Detailed Status

Active, not recruiting1

Recruiting1

Suspended1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

N/A1 (33.3%)

Trials by Status

active_not_recruiting125%

recruiting125%

suspended125%

terminated125%

Recent Activity

2 active trials

Showing 4 of 4

suspended

Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer

NCT05547347

recruitingphase_2

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

NCT07078604

active_not_recruitingnot_applicable

Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery

NCT02455791

terminatedphase_1

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

NCT06420349

Clinical Trials (4)

Showing 4 of 4 trials

NCT05547347

Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer

Suspended

NCT07078604Phase 2

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Recruiting

NCT02455791Not Applicable

Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery

Active Not Recruiting

NCT06420349Phase 1

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 4